ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded with the volume of 3.66 Million Yesterday. The Stock Opened its session at $27.94 and closed at 26.86 by showing an decrease of -1.94 percent. ACADIA Pharmaceuticals Inc. has 1 year price target of 44.78. The stock gained a consensus recommendation of 1.75 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The company is expected to report its next EPS (earnings per share) on Nov 03 AMC. The company reported its last quarter on Jun 16.
On Jun 16 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported its EPS in the last quarter as $-0.63/Share lagging the analyst estimate of $-0.49/Share by the difference of $-0.14. This showed the surprise of -28.6% in the last quarter earnings. For the Current Quarter, 1 analyst are projecting the mean EPS to be $-0.57/share. According to their observations and findings, the stock could provide a high EPS of $-0.57/share and a Low EPS of $-0.57/share.
The 9 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 45.00, with a high estimate of 60.00 and a low estimate of 39.00. The median estimate represents a +67.54% increase from the last price of 26.86. (CNN MONEY)
Many Analysts provided their foresight on Revenue Estimates of ACADIA Pharmaceuticals Inc. where they believe that the company has the potential to earn average revenue of $2.97 Million for the current quarter. According to their predictions High & Low revenue estimates are 7.04 Million and 740 Million respectively.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) topped its 52-week high price of $43.3 on Nov 4, 2015 and 52-Week Low Price of $16.64 on Feb 9, 2016. The Stock currently has the market capitalization of $3.28 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 5.36%% and monthly volatility of 5.04%% respectively.
ACADIA Pharmaceuticals Inc. Gross Margin percentage stands at 0% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of -19.4% with the 50-Day Simple Moving Average of -19.4 percent. Currently, the company has SMA200 (200-day simple moving average) of -10.57 Percent. The Stock has YTD (year to date) performance of -24.66 percent.
Many research firms have provided their ratings on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) where Leerink Partners provided Mkt Performrating on the stock on 4-Oct-16. Other firms include BofA/Merrill giving Neutral rating on 22-Jun-16.
The latest Insider trade was made on 15 Aug 2016 where Harrigan Edmund P Director did a transaction type “Buy” in which 1000 shares were traded at a price of $32.97. Another insider trade includes Beneficial Owner of More than 10% Class BAKER BROS ADVISORS L P who also initiated a transaction in which 133153 shares were traded on 9 Aug 2016 as “Buy”.
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.